Melanoma

Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025

NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope®…

3 months ago

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

Pilot studies have shown encouraging results that are supporting the company’s pre-IND enabling development, marking a critical step toward clinical…

3 months ago

Medical Care Technologies Inc. (OTC PINK:MDCE) Projects Debt-Free Status by Year-End Driven by Strong Subsidiary Growth

"Company anticipates achieving debt-free status by year-end, reinforcing commitment to AI-driven healthcare technologies" MESA, ARIZONA / ACCESS Newswire / September…

3 months ago

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology…

3 months ago

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approvalCompany…

3 months ago

Medical Care Technologies Inc. (OTC PINK:MDCE) Advances Skin Cancer Prevention with AI Mole Tracking System

MESA, ARIZONA / ACCESS Newswire / September 4, 2025 / Medical Care Technologies Inc. (OTC PINK: MDCE) is proud to…

4 months ago

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf…

4 months ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical…

4 months ago